Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B

Author： Veenstra David L.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.25, Iss.11, 2007-01, pp. : 963-977

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B

By Spackman D. Eldon   Veenstra David L.  

PharmacoEconomics, Vol. 26, Iss. 11, 2008-01 ,pp. : 937-949

Adis International

Access to resources Recommend Favorite

Entecavir of benefit in HBeAg-positive Hep B

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 542, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Lamivudine for the Treatment of Chronic Hepatitis B

By Crowley S.J.  

PharmacoEconomics, Vol. 17, Iss. 5, 2000-05 ,pp. : 409-427

Adis International

Access to resources Recommend Favorite

Evaluation of Hepatitis B Viraemia Levels in Patients with HBeAg-negative Chronic Hepatitis B Virus Infection

By Atay AE   Seven G   Yalcin K   Pasa S   Degertekin H  

The Journal of International Medical Research, Vol. 40, Iss. 5, 2012-09 ,pp. : 1891-1896

Field House Publishing

Access to resources Recommend Favorite

Lamivudine for the treatment of chronic hepatitis B

By Sokal Etienne  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 3, 2002-03 ,pp. : 329-339

Informa Healthcare

Access to resources Recommend Favorite